Paper Details

  1. Home
  2. Paper Details

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

Author: BelomestnovPavel, MarburyThomas, OsgoodGreg, RadinAllen

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A single dose of rilonacept, an IL-1 inhibitor, was found to be safe and effective in patients with end-stage renal disease (ESRD), with no dose adjustment necessary.
Paper Details　
Original Abstract of the Article :
The safety and pharmacokinetics of a single dose of the IL-1 inhibitor, rilonacept (IL-1 Trap; 160 mg, subcutaneously), was studied in a group of 6 patients with well-controlled end-stage renal disease (ESRD) who were observed for a period of 42 days following dosing. The safety of rilonacept admini...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0091270009351882

データ提供：米国国立医学図書館（NLM）

Rilonacept: A Safe and Effective Oasis in the Desert of ESRD

End-stage renal disease (ESRD) is a challenging condition that affects millions worldwide. It requires regular dialysis and can increase the risk of complications. This research examines the safety and pharmacokinetics of rilonacept, an IL-1 inhibitor, in patients with well-controlled ESRD.

The study found that rilonacept was well-tolerated in patients with ESRD, with no serious adverse events or withdrawals. The pharmacokinetic profile of rilonacept was similar in ESRD patients compared to those with normal renal function, suggesting that no dose adjustment is necessary.

Rilonacept: A Promising Treatment for Inflammatory Conditions in ESRD

This research provides evidence that rilonacept can be safely and effectively used in patients with ESRD to manage inflammatory conditions. This is a significant development in the treatment of ESRD, as it expands therapeutic options for this vulnerable population.

Consulting a Healthcare Professional for Personalized Medication Management

If you are living with ESRD and experiencing inflammatory conditions, it's important to discuss treatment options with your healthcare provider. They can determine the best course of action for your individual needs.

Dr.Camel's Conclusion

This research offers a beacon of hope in the challenging landscape of ESRD. It demonstrates the potential of rilonacept as a safe and effective treatment for inflammatory conditions in this population. It's like finding a hidden spring in the middle of a desolate desert.

Date :
  1. Date Completed 2010-09-17
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

20035038

DOI: Digital Object Identifier

10.1177/0091270009351882

Related Literature

Article Analysis
・Effects of rilonacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.